LEO Pharma Ranks Second in Global Clinical Trials Transparency Audit

PR69482

BALLERUP, Denmark and HURLEY, England, July 27, 2017 /PRNewswire=KYODO JBN/ --

    New top 50 list ranks LEO Pharma in second position, leading the global

pharma industry in commitments to increase access to clinical trials

information  

         (Logo: http://photos.prnewswire.com/prnh/20130221/595427 )

    The AllTrials audit on clinical trial transparency findings has been

published ranking LEO Pharma as leaders in the industry.

    LEO Pharma is ranked at number two out of the 50 pharmaceutical companies

evaluated. AllTrials is an international campaign that calls for every clinical

trial, past and present, to be registered and their results reported. The

rankings assess companies' policy commitments on disclosing trial

registrations, summary findings of studies, comprehensive clinical study

reports (CSRs) and individual patient data (IPD).

    As one of the companies in the forefront of data transparency LEO Pharma

was early off the mark to globally commit to increased disclosure. Since making

this commitment in 2013, LEO Pharma has made its clinical trials results dating

back to 1990 available to the public and will share individual patient-level

data upon request from qualified third-party researchers. The company's

commitment to transparency and patient focus has also evolved with the

completion of an innovative project to develop lay summaries for patients and

interested parties in easy to understand language.

    Commenting on the publication from AllTrials, Katherine Murphy, former CEO

of The Patients Association (now Independent Care Consultant) said:

    "I very much welcome these audit findings and greater transparency in

clinical trials, as well as research and development generally. It is really

pleasing to see more information on clinical trials becoming increasingly

available in the public domain with companies like LEO Pharma amongst the

leaders. The more information that patients and members of the public have will

support them to become better placed to make informed decisions and treatment

choices."

    Kim Kjoeller, Executive Vice President Global Research and Development, LEO

Pharma, said:

    "The AllTrials rankings are a robust overview which, while grounded in

empirical data, casts new light on the attitudes and approaches to transparency

across our industry. LEO Pharma welcomes the AllTrials audit and we are

delighted to see this positive recognition for our commitment to making our

scientific evidence base freely available for scrutiny and study. Having just

entered the biologics arena LEO Pharma is at a turning point in our company's

history, and we are excited by the promise that our pipeline holds. Maintaining

this commitment to openly sharing our vision through timely disclosure of trial

information has never been more important to us, and we look forward to  

continuing to partner with the scientific community to drive the clinical trial

transparency agenda to the next level."

    For more information on LEO Pharma's commitment to transparency, please see

the company's Position on Public Access to Clinical Trials Information at

http://www.leo-pharma.com.

    About LEO Pharma  

    LEO Pharma helps people achieve healthy skin. By offering care solutions to

patients in more than 100 countries globally, the company supports people in

managing their skin conditions.

    Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted

decades of research and development to delivering products and solutions to

people suffering from skin diseases.

    LEO Pharma is globally headquartered in Denmark and employs around 4,800

people worldwide.

    Contact:  

    Global Media Enquiries

    Henrik Kyndlev

    Corporate Communications Manager

    +45-3140-6180

    Henrik.kyndlev@leo-pharma.com

    UK and Ireland Media Enquiries

    Charlotte Murrain

    Communications Manager

    +44(0)7557-436-771

    charlotte.murrain@leo-pharma.com

    Julie Wong

    Head of Communications

    +44(0)7825-918-989

    julie.wong@leo-pharma.com

Source: LEO Pharma A/S